Retreatment With Radium-223 Safe, Showing Activity in Patients With CRPC and Bone Metastases

June 3-7, 2016; Chicago, Illinois
Results from this small exploratory study suggest that radium-223 retreatment is well tolerated and may help delay future bone events in patients with CRPC and bone metastases who experience radiographic or clinical progression following an initial course of radium-223.
Format: Microsoft PowerPoint (.ppt)
File Size: 525 KB
Released: June 7, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Downloadable slides from oncology nurse experts on nursing considerations for metastatic prostate cancer, from Clinical Care Options (CCO)

person default Kathleen Burns, MSN, AGACNP-BC, OCN
Program Director
person default Brenda Martone, MSN, ANP-BC, AOCNP
Program Director
Released: September 22, 2022

Downloadable guide for oncology nurses on optimal care of patients with metastatic prostate cancer, from Clinical Care Options (CCO)

person default Kathleen Burns, MSN, AGACNP-BC, OCN person default Brenda Martone, MSN, ANP-BC, AOCNP Released: September 14, 2022

Downloadable slideset highlighting current and emerging PSMA-targeted therapies for prostate cancer treatment

Karim Fizazi, MD, PhD Released: September 9, 2022

Clinical Care Options (CCO): Expert Karim Fizazi, MD, PhD, reviews key data on current and emerging therapies targeting PSMA for prostate cancer treatment

Karim Fizazi, MD, PhD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: September 9, 2022 Expired: September 8, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings